Mastek Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ewofvjb66su49269568ace4n.pdf

Key Takeaways


The UK Healthcare Pause: A Single-Account Shock

Hiral Chandrana: "This particular situation is a little bit unique and unfortunate. We won a very large deal six months, seven months back and we were able to really ramp up... there was a leadership change and that leadership change essentially combined three or four different departments in that account and really put a pause not just on our program, but a couple of other programs as well, because they were rethinking their entire strategy for how they wanted to deliver some of that output."

Deal Delays: Pushed, Not Cancelled

Hiral Chandrana: "The decision-making cycle that we saw in some of our cloud implementation has taken slightly longer than we expected and that's really what we are referring to. It could be due to the macro environment, it could be due to particular customer prioritization, but the deals are not cancelled, right."

MST Solutions: The Americas Growth Bet

Hiral Chandrana: "The spend of this state and local government still continues to be very high. And even with a recession type of environment, we like the healthcare and state and local government focus."

UK Public Sector: Stable and Growing

Hiral Chandrana: "As of right now, we don't see the political scenario impacting us in the core secure government services business that we currently have."

Margins, Cash, and People


Strategic Shifts: Annuity, Account Focus, and M&A Roadmap

Arun Agarwal: "Discretionary spend has to be seen from the eyes of the customers... most of this project has a significant ROI for the customer. But again when you get into discretionary and non-discretionary, depends on the priority of the customer, right."

Guidance & Commitments

CommitmentSpecificsTimeline
UK healthcare account recoveryPaused program returns in smaller, phased, standardized avatar; two to three other initiatives in same account pursued independentlyAt least one to two quarters to return to Q4FY22 run rate in that particular account
Americas organic growthExpect a decent jump in both order book and revenue growthH2FY23 (Q3 and Q4)
North America EBITDA marginOne-timer that drove significant margin correction expected to normalizeQ2FY23
DSO normalizationOne-time increase expected to settle back to quarterly run rateNext 90 days
MST integrationMost integration expected to be completeBefore end of FY23
Industry-beating growthExpect to start beating industry growth QoQ after recovery periodPost three to four quarters
Tax rate24% to 25% on a normalized basisFY23
EBITDA marginEndeavor to maintain high teens; closer to 20% depending on currencyOngoing
NHS framework dealsTwo deals, if converted, could offset healthcare pause impact; two more high-value deals ($30 mn–$50 mn) expected in the pipelineNear term (three to six months)
M&A roadmapThree to five acquisitions across cloud platforms and data/automation pillarsOver three to four years

Key Metrics

MetricQ1 FY23
Revenue₹570 cr, +13.4% YoY constant currency, flat QoQ
Operating EBITDA margin19.2%, vs 20.7% in Q4 FY22; impacted by GBP depreciation and salary increases
PAT₹84.4 cr (14.2% of income), vs ₹88.2 cr (14.7% of income) in Q4 FY22
Revenue from UK65%-plus of total revenue
Constant currency revenue growth13.4% YoY
Backlog growthOver 30% YoY
Gross cash₹665 cr, vs ₹794 cr in Q4 FY22
Cash net of debt₹490 cr, vs ₹600 cr in Q4 FY22
Headcount5,553, net addition of 576 resources during the quarter
New clients added33 during the quarter
Fortune 1,000 customer base21, vs 19 in Q4 FY22
Annuity business contribution30% to 35% of revenue; ambition to move closer to 50%
AttritionTrending downwards
DSOIncreased due to seasonality in a couple of customers and certain contract signatures; expected to normalize in Q2 FY23
Tax rate expectation for FY2324% to 25% on a normalized basis